Xencor (XNCR) Change in Receivables (2016 - 2026)
Xencor (XNCR) posted quarterly Change in Receivables of -$5.8 million for Q1 2026, up 75.22% year-over-year from -$3.3 million in Q1 2025, and up 75.22% quarter-over-quarter from -$23.4 million in Q1 2025.
Xencor (XNCR) Change in Receivables (2016 - 2026) Analysis & Trends
Xencor (XNCR) has reported Change in Receivables for 9 consecutive years, with -$5.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Receivables rose 75.22% year-over-year to -$5.8 million; the TTM figure through Mar 2026 stood at -$77.5 million (down 72.63% YoY), while the FY2025 annual figure was -$28.7 million, down 187.94% from the prior year.
- Change in Receivables advanced to -$5.8 million in Q1 2026 per XNCR's latest filing, from -$23.4 million in the prior quarter.
- Across five years, Change in Receivables topped out at $26.8 million in Q1 2022 and bottomed at -$38.9 million in Q2 2022.
- Historically, Change in Receivables has averaged -$10.1 million across 3 years, with a median of -$9.4 million in 2022.
- On a YoY basis, Change in Receivables climbed as much as 2378.74% in 2022 and fell as far as 301.24% in 2022.
- Xencor's Change in Receivables stood at -$9.4 million in 2022, then plunged by 148.78% to -$23.4 million in 2025, then jumped by 75.22% to -$5.8 million in 2026.
- Business Quant data shows XNCR's Change in Receivables at -$5.8 million in Q1 2026, -$23.4 million in Q1 2025, and -$9.4 million in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Xencor | 1.73 Bn | 1.36 Bn | - | 29.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.24 Mn |
| Jun 30, 2026 | 29.24 Mn |
| Mar 31, 2026 | -5.80 Mn |
| Mar 31, 2026 | -5.80 Mn |
| Mar 31, 2025 | -23.41 Mn |
| Mar 31, 2025 | -23.41 Mn |
| Sep 30, 2022 | -9.41 Mn |
| Sep 30, 2022 | -9.41 Mn |
| Jun 30, 2022 | -38.92 Mn |
| Jun 30, 2022 | -38.92 Mn |
| Mar 31, 2022 | 26.82 Mn |
| Mar 31, 2022 | 26.82 Mn |
| Dec 31, 2021 | 58.34 Mn |
| Dec 31, 2021 | 58.34 Mn |
| Sep 30, 2021 | 5.22 Mn |
| Sep 30, 2021 | 5.22 Mn |
| Jun 30, 2021 | -9.70 Mn |
| Jun 30, 2021 | -9.70 Mn |
| Mar 31, 2021 | 1.08 Mn |
| Mar 31, 2021 | 1.08 Mn |